Cargando…

Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis

PURPOSE: Ductal carcinoma in situ (DCIS) is present in more than half of HER2-positive invasive breast cancer (IBC). Recent studies show that DCIS accompanying HER2-positive IBC can be completely eradicated by neoadjuvant systemic therapy (NST). Our aim was to determine the percentage of pathologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ploumen, Roxanne A. W., Claassens, Eva L., Kooreman, Loes F. S., Keymeulen, Kristien B. M. I., van Kats, Maartje A. C. E., Gommers, Suzanne, Siesling, Sabine, van Nijnatten, Thiemo J. A., Smidt, Marjolein L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361905/ https://www.ncbi.nlm.nih.gov/pubmed/37395816 http://dx.doi.org/10.1007/s10549-023-07012-z

Ejemplares similares

Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis
por: Ploumen, Roxanne A. W., et al.
Publicado: (2023)

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
por: Goorts, Briete, et al.
Publicado: (2017)

ASO Author Reflections: Preoperative Prediction of Postmastectomy Radiation Therapy After Neoadjuvant Systemic Therapy
por: Samiei, Sanaz, et al.
Publicado: (2019)

Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer
por: de Mooij, Cornelis M., et al.
Publicado: (2023)

The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis
por: de Mooij, Cornelis M., et al.
Publicado: (2023)

Value of (18)F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype
por: de Mooij, Cornelis M., et al.
Publicado: (2021)

De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study
por: Simons, J. M., et al.
Publicado: (2020)

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry
por: Meegdes, Marissa, et al.
Publicado: (2022)

Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis
por: Simons, Janine M., et al.
Publicado: (2019)

Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study
por: van Roozendaal, Lori M., et al.
Publicado: (2016)

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
por: van Roozendaal, L. M., et al.
Publicado: (2016)

Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients
por: de Mooij, Cornelis Maarten, et al.
Publicado: (2020)

MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
por: Goorts, Briete, et al.
Publicado: (2018)

Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study
por: van Nijnatten, Thiemo J. A., et al.
Publicado: (2017)

Differences in degree of lesion enhancement on CEM between ILC and IDC
por: van Nijnatten, Thiemo JA, et al.
Publicado: (2019)

Diagnostic performance of standard breast MRI compared to dedicated axillary MRI for assessment of node-negative and node-positive breast cancer
por: Samiei, Sanaz, et al.
Publicado: (2020)

MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study
por: Granzier, Renée W. Y., et al.
Publicado: (2021)

The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions
por: Beugels, J., et al.
Publicado: (2019)

Clinical value of contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: a population-based cohort study
por: Keymeulen, Kristien B. I. M., et al.
Publicado: (2022)

The prognostic value of the histological shape of tumor negative sentinel nodes in breast cancer
por: Kooreman, Loes F. S., et al.
Publicado: (2023)

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
por: Iwata, Hiroji, et al.
Publicado: (2018)

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
por: Howell, Sacha J., et al.
Publicado: (2020)

Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015)

Repeat breast-conserving treatment of ipsilateral breast cancer recurrence: a nationwide survey amongst breast surgeons and radiation oncologists in the Netherlands
por: Walstra, Coco J. E. F., et al.
Publicado: (2021)

The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery
por: Nussbaumer, R. L., et al.
Publicado: (2022)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
por: Lynce, F., et al.
Publicado: (2019)

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations
por: Hendriks, Mathijs P., et al.
Publicado: (2020)

Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction
por: Samiei, S., et al.
Publicado: (2019)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
por: Parker, Barbara A., et al.
Publicado: (2023)

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2‐Positive Breast Cancer: A Phase II Clinical Trial
por: Xuhong, Juncheng, et al.
Publicado: (2020)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
por: Liefaard, M. C., et al.
Publicado: (2023)

ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Patients’ perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict
por: van Steenhoven, Julia E. C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nu7o8om8aljds0dhil0ok4ml7d